Why Glaukos Stock Zoomed Almost 14% Higher on Thursday

Glaukos (NYSE: GKOS), a biotech and pharmaceutical company focused on eye disorders, was the focus of the right kind of investor attention on Thursday. Market players bid the company's stock up by nearly 14% that trading session, thanks almost entirely to a solid quarterly earnings report. The stock's performance was particularly impressive given the S&P 500's (SNPINDEX: ^GSPC) 1% decrease. Glaukos set a new record for net sales in its third quarter; these came in at $133.5 million, for a 38% year-over-year improvement. This was fueled by sales of glaucoma treatments, which also set a fresh all-time high with net sales of $110 million (45% higher than in the same period of 2024). Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool